Protagonist Therapeutics
PTGX
156 hedge funds and large institutions have $1.34B invested in Protagonist Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 60 reducing their positions, and 19 closing their positions.
488% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $2.47M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
42% more capital invested
Capital invested by funds: $946M → $1.34B (+$399M)
8% more funds holding
Funds holding: 144 → 156 (+12)
3.11% more ownership
Funds ownership: 98.58% → 101.69% (+3.1%)
33% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$34.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.3M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$14.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.4M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$7.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$27.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$21.2M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$18.5M |
| 4 |
PA
Perceptive Advisors
New York
|
-$11.7M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$7.61M |
PTGX Hedge Fund Activity: Q4 2023 in Review
156 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2023, worth a combined $1.34B — up 42% from $946M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new PTGX positions and 19 closed out — a net gain of 13 holders — while 40 added to existing stakes and 60 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $34.2M. The largest seller was Cowen and Company, exiting entirely with an estimated $27.6M sold.
- 156 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2023, up from 144 in Q3 2023.
- Funds reported $1.34B of Protagonist Therapeutics stock for Q4 2023, up 42% quarter-over-quarter.
- 32 funds opened new Protagonist Therapeutics positions in Q4 2023 and 19 closed out, a net change of +13 holders.
- The largest Protagonist Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $34.2M added.
- The largest Protagonist Therapeutics seller in Q4 2023 was Cowen and Company, an estimated $27.6M sold.
Based on aggregated 13F filings for Q4 2023.